Case-control analysis shows FOXO4DRI alters histological changes in the intestine, indicating potential for targeted aging therapies.
To identify patterns of histological changes in the small and large intestines of white mice, as well as to evaluate the corrective potential of senolytic agents in these conditions, the authors conducted a study using outbred white mice selected based on a case-control design. A selective p53 activator – FOXO4DRI – was used. On day 14 following doxorubicin administration, the results obtained allowed for key conclusions regarding the presence of distinct sex-based differences in response to equivalent doses of doxorubicin. The senolytic agent FOXO4DRI demonstrated a pronounced pro-apoptotic effect, particularly in labile cell populations. Additionally, the intensity of the response to the drug showed a dose-dependent pattern.
No takes yet. Share an insight, caveat, or question.
Yakovlev et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: